Emily E. Van Seventer
Harvard University · 161 works · 4,710 citations · h-index 23
Top works
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
- Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
- TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
- Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
- Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
- Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
- Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
- Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer
- Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
- Computed Tomography–based Body Composition Analysis and Its Role in Lung Cancer Care
- Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer.
- Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer
- Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
- Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer
- A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
- Percentile‐based averaging and skeletal muscle gauge improve body composition analysis: validation at multiple vertebral levels
- Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss